Inactive

Solicitation Amendment is adding on the Second Newborn Screening to the base and option years COMBINED SYNOPSIS/SOLICITATION W81K00-21-Q-0242 This is a combined synopsis/solicitation for commercial se... Solicitation Amendment is adding on the Second Newborn Screening to the base and option years COMBINED SYNOPSIS/SOLICITATION W81K00-21-Q-0242 This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in FAR Subpart 12.6 and using the procedures of FAR Part 13--Simplified Acquisition Procedures, as supplemented with additional information included in this notice. The solicitation number is W81K00-21-Q-0242 and it is issued as a Request for Quote (RFQ). This announcement constitutes the only RFQ that will be posted. A separate written solicitation document will be not be issued. This document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2021-05 and the Defense Federal Acquisition Regulation Supplement Publication Notice (DPN) 20210224. This solicitation is for First and Second Newborn Screening for patients at Weed Army Community Hospital, Fort Irwin, CA. The period of performance is 1 Oct 2021 – 30 Sept 2022, followed by four (4) twelve month option periods. The North American Industrial Classification System (NAICS) code for this procurement is 621511, Medical Laboratories with a size standard of $35M. This acquisition is be conducted as a full and open competition. All eligible entities may submit an offer, which will be considered. Solicitation incorporates by reference FAR 52.212-1, 52.212-2, 52.212-3, 52.212-4 & 52.212-5 are attached. Addenda are attached. The Point of Contact (POC) for this RFQ is Ms. Kimberly Macias. Offers and Questions shall be submitted to the POCs via e-mail at kimberly.r.macias.civ@mail.mil . Quoters shall reference the following FAR Provisions and their Addendums to prepare and submit their offer: FAR Provision 52.212-1-Instructions to Offerors—Commercial Items and its Addendum; and, FAR Provision 52.212-2 Evaluation—Commercial Items and its Addendum. Offers are due on or before 25 August 2021 at 1:00 PM Central Time. Offers received after this date and time will be considered untimely and not eligible for award. Questions shall be submitted via email not later than 20 August 2021, 3:00 PM Central Time. Government reserve the right not to answer questions received after this date/time. The screening shall include the following minimum testing requirements: Cystic Fibrosis, Endocrine Disorders, Metabolic Disorders, (via Mass Spec MS/MS Screening); Amino Acid Disorders, Organic Acid Disorders, Fatty Acid Oxidation Disorders, Other Metabolic Disorders to include; Classical Galactosemia, and Biotinidase Deficiency.; Severe Combined Immunodeficiency (SCID); Hemoglobin Disorders; sickle cell anemia (Hb S/S disease); • sickle C disease (Hb S/C disease), • sickle D disease (Hb S/Ddisease), • sickle E disease (Hb S/E disease), • Hb S/ hereditary persistence of fetal hemoglobin (Hb S/HPFH), sickle cell disease variant (other sickle cell disease, Hb S/V), • Hb S/ Beta0 thalassemia, • Hb S/Beta + thalassemia, • Hb C disease (Hb CC), • Hb D disease (Hb DD), • alpha thalassemia major, • Hb H disease (3 gene deletion), • Hb H/ Constant Spring disease, • beta thalassemia major, • Hb E/ Beta0 thalassemia, • Hb E/Beta+ thalassemia, • Hb E/ Delta Beta thalassemia, • Hb C/ Beta0 thalassemia • Hb C/Beta+ thalassemia, • Hb D/ Beta0 thalassemia, • Hb D/Beta+ thalassemia, • Hb Variant/ Beta0 thalassemia, • Hb Variant/Beta+ thalassemia, • other hemoglobinopathies (Hb variants) Offerors shall complete the below with offer: OFFEROR: (Business Name): CAGE Code: DUNS: ORDERING POC (Print) Name Date: Signature